Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT06647134

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Conditions: Arthritis, Polymyalgia Rheumatica, Immune Checkpoint Inhibitors

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 20

Sponsor: M.D. Anderson Cancer Center

Location: MD Anderson Cancer Center Houston Texas

Summary

To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.

Eligibility Criteria

Inclusion Criteria The criteria are: * Patients aged 18 years and above * English (conversational level) speaking, with the ability to give informed consent * Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy Exclusion Criteria * Acutely life-threatening or worsening cancer * Hearing impairment functionally limiting participation in verbal interview

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06647134). StuddyBuddy aggregates publicly available trial information.